154 related articles for article (PubMed ID: 28494348)
1. Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer.
Moselhy J; Suman S; Alghamdi M; Chandarasekharan B; Das TP; Houda A; Ankem M; Damodaran C
Neoplasia; 2017 Jun; 19(6):451-459. PubMed ID: 28494348
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model.
Suman S; Das TP; Moselhy J; Pal D; Kolluru V; Alatassi H; Ankem MK; Damodaran C
Oncotarget; 2016 Aug; 7(33):53751-53761. PubMed ID: 27447565
[TBL] [Abstract][Full Text] [Related]
3. Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.
Hafeez BB; Fischer JW; Singh A; Zhong W; Mustafa A; Meske L; Sheikhani MO; Verma AK
Cancer Prev Res (Phila); 2015 May; 8(5):375-86. PubMed ID: 25627799
[TBL] [Abstract][Full Text] [Related]
4. Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells.
Suman S; Das TP; Sirimulla S; Alatassi H; Ankem MK; Damodaran C
Oncotarget; 2016 Mar; 7(12):13854-64. PubMed ID: 26883103
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.
Das TP; Suman S; Alatassi H; Ankem MK; Damodaran C
Cell Death Dis; 2016 Feb; 7(2):e2111. PubMed ID: 26913603
[TBL] [Abstract][Full Text] [Related]
6. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
7. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
[TBL] [Abstract][Full Text] [Related]
8. FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
Ma L; He H; Jiang K; Jiang P; He H; Feng S; Chen K; Shao J; Deng G
Aging (Albany NY); 2020 Apr; 12(7):6352-6369. PubMed ID: 32283544
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.
Rodriguez M; Siwko S; Zeng L; Li J; Yi Z; Liu M
Oncogene; 2016 Mar; 35(9):1153-62. PubMed ID: 26028029
[TBL] [Abstract][Full Text] [Related]
10. Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21.
Zhou B; Wang J; Zheng G; Qiu Z
Food Chem Toxicol; 2016 Nov; 97():375-384. PubMed ID: 27725205
[TBL] [Abstract][Full Text] [Related]
11. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
12. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
15. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
[TBL] [Abstract][Full Text] [Related]
16. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
17. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
18. A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
Oncotarget; 2016 Dec; 7(52):86087-86102. PubMed ID: 27863384
[TBL] [Abstract][Full Text] [Related]
19. Withaferin A suppresses the up-regulation of acetyl-coA carboxylase 1 and skin tumor formation in a skin carcinogenesis mouse model.
Li W; Zhang C; Du H; Huang V; Sun B; Harris JP; Richardson Q; Shen X; Jin R; Li G; Kevil CG; Gu X; Shi R; Zhao Y
Mol Carcinog; 2016 Nov; 55(11):1739-1746. PubMed ID: 26472150
[TBL] [Abstract][Full Text] [Related]
20. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]